Your SlideShare is downloading. ×
Hypertensive disorders of pregnancy
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.


Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Hypertensive disorders of pregnancy


Published on

Published in: Health & Medicine

  • Be the first to comment

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide
  • most common within 24 hrs
  • Impaired remodelling of spiral a. Imcomplete trophoblast invasion  The deeper myometrial arterioles do not lose their endothelial lining and musculoelastic tissue, and their mean external diameter is only half that of vessels in normal placentas  release of placental debris that incites a systemic inflammatory response
  • Visual symptoms: retinal detachment Epigastric pain: abruptio placenta Rapid
  • Nifedipine and MgSO 4 can be used contemporaneously.
  • Rationale: preeclampsia woman are intravascularly volume contracted
  • NSAID: may exacerbate non-pregnancy hypertension, elevated CRE, renal failure
  • Transcript

    • 1. Ri 簡睦旼 2012/5/3
    • 2. Classification  Pregnancy-induced hypertension (Gestational hypertension)5-10%  Preeclampsia3.9%  Eclampsia  Preeclampsia superimposed on chronic hypertension  Chronic hypertension William’s Obstertrics, 23ed
    • 3. Gestationa Pre- Eclampsia l HTN Eclampsia Superimposed Preeclampsia SBP≥140 Proteinuria Generalized or seizures DBP ≥ 90 Severe Preeclampsia ≥ 0.3 g/ 24hr> GA 20th wk before , during >30 mg/dL< PP 12th wk or after labor (1+ on dipstick) HELLP syndrome
    • 4. Preeclampsia 2~7% of healthy nulliparous; 0.8~5% of multiparous women The third leading cause of maternal mortality (17%) A major cause of neonatal morbidity and mortality (intrauterine growth restriction, abruptio placentae and the need for preterm delivery) Preeclampsia Deadly Triad Hemorrhage Infection
    • 5. Severe preeclampsia BP 160/110 mm Hg Proteinuria 2.0 g/24 hours or 2+ dipstick Increase severity /certainty  Serum creatinine >1.2 mg/dL unless known to be previously elevated  Platelets < 100,000/L  Microangiopathic hemolysis—increased LDH  Elevated serum transaminase levels—ALT or AST  Persistent headache or other cerebral or visual disturbance  Persistent epigastric pain
    • 6. Superimposed Chronic Preeclampsia HTN SBP≥140 or Proteinuria DBP ≥ 90< GA 20th wk > 20th GA wk> PP 12th wk HTN + PTuria b4 20wk ↑proteinuria or ↑BP or PLT < 100,000/L
    • 7. Risk factors  Nulliparity  Age >35 years (superimposed) or teenager  Obesity  Multifetal gestation  Medical illness: Chronic hypertension, lupus erythematosus, IDDM, APS, PT C/S deficiency, renal disease  Genetic: Hx / FH of previous preeclampsia or eclampsia  Hydatidiform moles  Smoking, placenta previa
    • 8. ↓NO, PGE2, PGI2, PlGF, VEGF ↑TXA2, Endothelin Stage 1 PoorPlacentation Vasoconstriction Endothelial Stage 2 Cytokines integrity ↓ Placental oxidative Antiangiogenic stress Endothelial peptides damage sFlt-1,sEng
    • 9. Endothelial integrity ↓Vasoconstriction Endothelial damage MAHA HELLP
    • 10. Principle of management Difinitive treatment is delivery BP control Seizure prophylaxis
    • 11. Evaluation of a new-onset HTN Clinical findings:  headache, visual disturbance, epigastric pain, rapid weight gain… Measure BW QD Analysis for proteinuria on admission and QOD BP measurement Q4H CRE, AST/ALT, CBC (for PLT). UA? LDH? Coagulation profile? Sonography: fetal size, amnionic fluid William’s Obstertrics, 23ed
    • 12. Management of HTN disorder Dietary Lifestyle Place of care Antihypertensive therapy Corticosteroids Mode of delivery
    • 13. Management of HTN disorder Dietary  Salt restriction is not recommended  Insufficient evidence to make recommendation Lifestyle  Avoid vigorous exercise  Bed rest? Place of care  Severe hypertension or preeclampsia (BP>160/110)should be hospitalized Laura Magee et al, 2008, JOGC
    • 14. Management of HTN disorder Antihypertensive therapy  For severe hypertension (BP>160/110)  BP goal: <160/110  Initial antihypertensive: labetalol, nifedipine hydralazine.  MgSO 4 is not recommended as antihypertensive (only transient decrease in 30 mins)  Continuous FHR monitoring is advised until BP is stable. Laura Magee et al, 2008, JOGC
    • 15. Management of HTN disorder Antihypertensive therapy  Non-severe hypertension (BP:140-159/90-109 mmHg)  BP goal: w/o cormorbid - 130-155/80-105 w/ cormorbid – 130-139/80-89  Drug of choice: methyldopa, labetalol, other beta- blockers, CCB (nifedipine). (I-A)  ACEi and ARBs should not beused. (II-2E)  Atenolol and prazosin are not recommended. Laura Magee et al, 2008, JOGC
    • 16. Management of HTN disorder Mode of delivery  Induction of labour  Vaginal delivery, unless C/S is indicated  Oxytocin at 3rd stage of labor, esp. thrombocytopenia or coagulopathy  Ergometrine should not be given Laura Magee et al, 2008, JOGC
    • 17. Management of HTN disorder Corticosteroids  To accelerate fetal pulmonary maturity  Pre-eclampsia & GA < 34 wks  Gestational HTN & GA < 34 wks, about to deliver within next 7 days Laura Magee et al, 2008, JOGC
    • 18. Management of Pre-eclampsia Delivery is the only cure Timing of delivery MgSO4 Plasma volume expansion Laura Magee et al, 2008, JOGC
    • 19. Management of Pre-eclampsia Timing of delivery  GA < 34 wks: expectant management  GA: 34-36 wks, non-severe pre-eclampsia: debated  GA > 37 wks: immediate delivery Laura Magee et al, 2008, JOGC
    • 20. William’s Obstertrics, 23ed
    • 21. Management of Pre-eclampsia MgSO4  First-line Tx for eclampsia  Prophylaxis against eclampsia in severe- preeclampsia  Phenytoin and BZD should not be used for eclampsia prophylaxis, unless MgSO4 is contraindicated or ineffective Plasma volume expansion  Not recommended Laura Magee et al, 2008, JOGC
    • 22. Management for HELLPsyndrome PLT count > 50x109 /L  Prophylactic transfusion of platelets is not recommended  Consider ordering blood when PLT drop rapidly PLT count < 20 x 109 /L.  Platelet transfusion prior to vaginal delivery or C/S) Corticosteriods may be considered for PLT count < 50x109 /L Plasma exchange or plasmapheresis? Laura Magee et al, 2008, JOGC
    • 23. Postpartum treatment BP follow-up  Peak postpartum, D3, D6 Antihypertensive therapy may be restart, BP goal <160/110 mmHg  Acceptable in breastfeeding: Nifedipine, labetalol, methyldopa, captopril, enalapril NSAID should be avoid if hypertension is difficult to control, or oliguria, CRE ↑, PLT↓ Thromboporphylaxis may be considered Laura Magee et al, 2008, JOGC